These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 21308478

  • 1. Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.
    Raymond E, Hobday T, Castellano D, Reidy-Lagunes D, García-Carbonero R, Carrato A.
    Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():19-26. PubMed ID: 21308478
    [Abstract] [Full Text] [Related]

  • 2. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY, Grossman AB, Bukowski RM.
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [Abstract] [Full Text] [Related]

  • 3. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.
    Oberg K.
    Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940
    [Abstract] [Full Text] [Related]

  • 4. From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors.
    Wiedenmann B, Pavel M, Kos-Kudla B.
    Neuroendocrinology; 2011 Jul; 94(3):177-90. PubMed ID: 21893937
    [Abstract] [Full Text] [Related]

  • 5. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
    Faivre S, Sablin MP, Dreyer C, Raymond E.
    Endocrinol Metab Clin North Am; 2010 Dec; 39(4):811-26. PubMed ID: 21095547
    [Abstract] [Full Text] [Related]

  • 6. [Neuroendocrine tumors: the age of targeted therapies].
    Capdevila J, Argilés G, Mulet-Margalef N, Tabernero J.
    Endocrinol Nutr; 2012 Dec; 59(7):438-51. PubMed ID: 22565119
    [Abstract] [Full Text] [Related]

  • 7. Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
    Oberstein PE, Saif MW.
    JOP; 2011 Jul 08; 12(4):358-61. PubMed ID: 21737896
    [Abstract] [Full Text] [Related]

  • 8. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP.
    Gastroenterology; 2010 Sep 08; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
    Ganetsky A, Bhatt V.
    Ann Pharmacother; 2012 Jun 08; 46(6):851-62. PubMed ID: 22589450
    [Abstract] [Full Text] [Related]

  • 12. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
    Maione P, Gridelli C, Troiani T, Ciardiello F.
    Oncologist; 2006 Mar 08; 11(3):274-84. PubMed ID: 16549812
    [Abstract] [Full Text] [Related]

  • 13. Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours.
    Srirajaskanthan R, Toumpanakis C, Meyer T, Caplin ME.
    Aliment Pharmacol Ther; 2009 Jun 01; 29(11):1143-54. PubMed ID: 19298583
    [Abstract] [Full Text] [Related]

  • 14. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin.
    Basu B, Sirohi B, Corrie P.
    Endocr Relat Cancer; 2010 Mar 01; 17(1):R75-90. PubMed ID: 20008097
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors.
    Pavel ME, Wiedenmann B.
    Horm Metab Res; 2011 Nov 01; 43(12):844-53. PubMed ID: 22105475
    [Abstract] [Full Text] [Related]

  • 17. Pancreatic neuroendocrine tumors: entering a new era.
    Oberstein PE, Remotti H, Saif MW, Libutti SK.
    JOP; 2012 Mar 10; 13(2):169-73. PubMed ID: 22406593
    [Abstract] [Full Text] [Related]

  • 18. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
    Höpfner M, Baradari V, Huether A, Schöfl C, Scherübl H.
    Endocr Relat Cancer; 2006 Mar 10; 13(1):135-49. PubMed ID: 16601284
    [Abstract] [Full Text] [Related]

  • 19. Advances in the systemic treatment of pancreatic neuroendocrine tumors.
    Yalcin S.
    Cancer Treat Rev; 2011 Apr 10; 37(2):127-32. PubMed ID: 20705397
    [Abstract] [Full Text] [Related]

  • 20. Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors.
    Capdevila J, Salazar R, Halperín I, Abad A, Yao JC.
    Cancer Metastasis Rev; 2011 Mar 10; 30 Suppl 1():27-34. PubMed ID: 21311955
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.